EP3596203A4 - Rationale polyploid-adeno-assoziierte virusvektoren und verfahren zur herstellung und verwendung davon - Google Patents
Rationale polyploid-adeno-assoziierte virusvektoren und verfahren zur herstellung und verwendung davon Download PDFInfo
- Publication number
- EP3596203A4 EP3596203A4 EP18907477.6A EP18907477A EP3596203A4 EP 3596203 A4 EP3596203 A4 EP 3596203A4 EP 18907477 A EP18907477 A EP 18907477A EP 3596203 A4 EP3596203 A4 EP 3596203A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- rational
- making
- methods
- same
- associated virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000702421 Dependoparvovirus Species 0.000 title 1
- 208000020584 Polyploidy Diseases 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862668056P | 2018-05-07 | 2018-05-07 | |
US201862678675P | 2018-05-31 | 2018-05-31 | |
PCT/US2018/044632 WO2019216932A1 (en) | 2018-05-07 | 2018-07-31 | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3596203A1 EP3596203A1 (de) | 2020-01-22 |
EP3596203A4 true EP3596203A4 (de) | 2021-12-01 |
Family
ID=68468205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18907477.6A Pending EP3596203A4 (de) | 2018-05-07 | 2018-07-31 | Rationale polyploid-adeno-assoziierte virusvektoren und verfahren zur herstellung und verwendung davon |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3596203A4 (de) |
JP (2) | JP2021522775A (de) |
CN (2) | CN110691846A (de) |
AU (1) | AU2018422759A1 (de) |
WO (1) | WO2019216932A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110684800B (zh) * | 2018-11-02 | 2020-11-03 | 深圳益世康宁生物科技有限公司 | 一种携带肿瘤-睾丸抗原10基因的重组腺相关病毒载体及其应用价值 |
US20240189447A1 (en) * | 2021-04-16 | 2024-06-13 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
WO2022253955A2 (en) * | 2021-06-02 | 2022-12-08 | Uniqure Biopharma B.V. | Insect cell production of parvoviral vectors with modified capsid proteins |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060088936A1 (en) * | 2002-05-01 | 2006-04-27 | Warrington Kenneth H | Raav expression systems for genetic modification of specific capsid proteins |
US20130296409A1 (en) * | 2010-11-10 | 2013-11-07 | Fred Hutchinson Cancer Research Center | Compositions and methods for generating adeno-associated viral vectors with undetectable capsid gene contamination |
WO2018170310A1 (en) * | 2017-03-15 | 2018-09-20 | The University Of North Carolina At Chapel Hill | Polyploid adeno-associated virus vectors and methods of making and using the same |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004099423A1 (en) * | 2003-05-01 | 2004-11-18 | University Of Florida Research Foundation, Inc. | Vp2-modified raav vectors and uses thereof |
JP5588586B2 (ja) * | 2003-09-02 | 2014-09-10 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
WO2007149852A2 (en) * | 2006-06-19 | 2007-12-27 | Asklepios Biopharmaceutical, Inc. | Modified factor viii and factor ix genes and vectors for gene therapy |
WO2012112578A2 (en) * | 2011-02-14 | 2012-08-23 | The Children's Hospital Of Philadelphia | Improved aav8 vector with enhanced functional activity and methods of use thereof |
GB201103062D0 (en) * | 2011-02-22 | 2011-04-06 | Isis Innovation | Method |
SG10201809075XA (en) * | 2013-07-22 | 2018-11-29 | Childrens Hospital Philadelphia | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
-
2018
- 2018-07-31 AU AU2018422759A patent/AU2018422759A1/en active Pending
- 2018-07-31 CN CN201880032343.2A patent/CN110691846A/zh active Pending
- 2018-07-31 WO PCT/US2018/044632 patent/WO2019216932A1/en unknown
- 2018-07-31 CN CN202311045266.3A patent/CN117535247A/zh active Pending
- 2018-07-31 JP JP2019565168A patent/JP2021522775A/ja active Pending
- 2018-07-31 EP EP18907477.6A patent/EP3596203A4/de active Pending
-
2023
- 2023-08-02 JP JP2023125955A patent/JP2023154428A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060088936A1 (en) * | 2002-05-01 | 2006-04-27 | Warrington Kenneth H | Raav expression systems for genetic modification of specific capsid proteins |
US20130296409A1 (en) * | 2010-11-10 | 2013-11-07 | Fred Hutchinson Cancer Research Center | Compositions and methods for generating adeno-associated viral vectors with undetectable capsid gene contamination |
WO2018170310A1 (en) * | 2017-03-15 | 2018-09-20 | The University Of North Carolina At Chapel Hill | Polyploid adeno-associated virus vectors and methods of making and using the same |
Non-Patent Citations (1)
Title |
---|
ZHENG CHAI ET AL: "Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion", JOURNAL OF CONTROLLED RELEASE, vol. 262, 1 September 2017 (2017-09-01), AMSTERDAM, NL, pages 348 - 356, XP055713109, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2017.08.005 * |
Also Published As
Publication number | Publication date |
---|---|
CN117535247A (zh) | 2024-02-09 |
WO2019216932A1 (en) | 2019-11-14 |
JP2021522775A (ja) | 2021-09-02 |
JP2023154428A (ja) | 2023-10-19 |
CN110691846A (zh) | 2020-01-14 |
AU2018422759A1 (en) | 2020-01-02 |
EP3596203A1 (de) | 2020-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3610023A4 (de) | Polyploide adeno-assoziierte virusvektoren und verfahren zur herstellung und verwendung davon | |
EP3684423A4 (de) | Variante kapside mit adeno-assoziiertem virus und verfahren zur verwendung davon | |
EP3634430A4 (de) | Multibiotika und verwendungsverfahren dafür | |
EP3684821A4 (de) | Anti-hla-a2-antikörper und verfahren zur verwendung davon | |
EP3633034A4 (de) | Modifiziertes cas9-protein und verwendung davon | |
EP3638726A4 (de) | Faserverstärkte formmassen und verfahren zu ihrer herstellung und verwendung | |
EP3759218A4 (de) | Verfahren und zusammensetzungen für antikörperausweichende virusvektoren | |
EP3568469A4 (de) | Hla-dr-cart-zusammensetzungen und verfahren zur herstellung und verwendung davon | |
EP3814487A4 (de) | Struktur des menschlichen cgas-dna-komplexes und dessen verwendungen | |
EP3680331A4 (de) | Modifiziertes cas9-protein und verwendung davon | |
EP3678701A4 (de) | Therapeutische proteinzusammensetzungen und verfahren zur herstellung und verwendung davon | |
EP3740576A4 (de) | Therapeutische zusammensetzungen und verfahren zur herstellung und verwendung davon | |
EP3577264A4 (de) | Abstandsgewebe und verfahren zur herstellung davon | |
EP3833361A4 (de) | Supersaugfähige materialien und herstellungsverfahren dafür | |
EP3419425A4 (de) | Garvorrichtungen und verfahren zur verwendung davon | |
EP3836971A4 (de) | Konjugate und verfahren zur verwendung davon | |
EP3377085A4 (de) | Peptide und verfahren zur behandlung von endometriose damit | |
EP3768408A4 (de) | Halloysitbasierte nanokomposite und verfahren zur herstellung und verwendung davon | |
EP3679607A4 (de) | Organisch-anorganische perowskitmaterialien und verfahren zu ihrer herstellung | |
IL282939A (en) | Mixtures and preparations containing 5-fluoro-4-imino-3-methyl-1-tosyl-4,3-dihydropyrimidin-2-one and methods of using them | |
EP3596203A4 (de) | Rationale polyploid-adeno-assoziierte virusvektoren und verfahren zur herstellung und verwendung davon | |
EP3805386A4 (de) | Modifiziertes cas9-protein und verwendung davon | |
EP3813861A4 (de) | Heparin-assoziierte polypeptide und deren verwendung | |
EP3740228A4 (de) | Peptide und ihre verwendungen | |
EP3861219A4 (de) | Verriegelungsvorrichtung und möbelstück mit einer solchen verriegelung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190905 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
R17P | Request for examination filed (corrected) |
Effective date: 20190905 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40020633 Country of ref document: HK |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20211102 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/86 20060101ALI20211026BHEP Ipc: A61K 48/00 20060101ALI20211026BHEP Ipc: C12N 5/10 20060101ALI20211026BHEP Ipc: C12N 15/864 20060101ALI20211026BHEP Ipc: C12N 15/35 20060101ALI20211026BHEP Ipc: C12N 7/00 20060101AFI20211026BHEP |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230524 |